Visual Abstract.
Metabolic tumor volume showed higher predictive value for progression-free
survival than the established International Prognostic Index across multiple
analytical methods in patients with large B-cell lymphoma undergoing CAR T-cell
therapy.
The authors of "Risk Assessment in Large B-Cell Lymphoma
Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of
Patients Undergoing CAR T-Cell Therapy" include Conrad-Amadeus Voltin, Alexander Drzezga, and Markus
Dietlein, Department of Nuclear Medicine, Faculty of Medicine and University
Hospital Cologne, University of Cologne, Cologne, Germany; Sarah Flossdorf, Institute
for Medical Informatics, Biometry, and Epidemiology, University Hospital Essen,
University of Duisburg Essen, Essen, Germany; Lars Kurch, Department
of Nuclear Medicine, University Hospital Leipzig, University of Leipzig,
Leipzig, Germany, and Department of Anesthesiology and Surgical Intensive Care, University
Hospital Halle, Martin Luther University Halle Wittenberg, Halle, Germany;
Michael Winkelmann and Wolfgang G. Kunz, Department of Radiology, University
Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany; Andrea
Farolfi, Division of Nuclear Medicine, Scientific Institute for Research,
Hospitalization, and Healthcare Azienda Ospedaliero Universitaria di Bologna , University of Bologna, Bologna,
Italy; Laura Beckmann, Nadine Kutsch, Peter Borchmann, Jan-Michel Heger, and
Philipp G del, Department I of Internal Medicine, Faculty of Medicine and
University Hospital Cologne, University of Cologne, Cologne, Germany; Beatrice
Casadei, L. e A. Ser gnoli Institute of Hematology,
Scientific Institute for Research, Hospitalization, and Healthcare Azienda Ospedaliero Universitaria di
Bologna , University of Bologna, Bologna, Italy; Ken Herrmann, Department of
Nuclear Medicine, University Hospital Essen, University of Duisburg Essen,
Essen, Germany; Matthias Brendel and Gabriel T. Sheikh, Department of Nuclear
Medicine, University Hospital Munich, Ludwig Maximilian University Munich,
Munich, Germany; Viktoria Blumenberg and Marion Subklewe, Department of
Medicine III, University Hospital Munich, Ludwig Maximilian University Munich,
Munich, Germany and Laboratory for Translational Cancer Immunology, Gene Center
Munich, Ludwig Maximilian University Munich, Munich, Germany; Stefano Fanti, Division
of Nuclear Medicine, Scientific Institute for Research, Hospitalization, and
Healthcare Azienda Ospedaliero Universitaria
di Bologna , University of Bologna, Bologna, Italy, and Department of Medical
and Surgical Sciences, University of Bologna, Bologna, Italy; Pier Luigi Zinzani,
L. e A. Ser gnoli Institute of Hematology,
Scientific Institute for Research, Hospitalization, and Healthcare Azienda Ospedaliero Universitaria di
Bologna , University of Bologna, Bologna, Italy, and Department of Medical and
Surgical Sciences, University of Bologna, Bologna, Italy; Kambiz Rahbar, Department
of Nuclear Medicine, University Hospital M nster, University of M nster,
M nster, Germany; Osama Sabri, Department of Nuclear Medicine, University
Hospital Leipzig, University of Leipzig, Leipzig, Germany; H. Christian
Reinhardt, Bastian von Tresckow, and Christine
Hanoun, Department of Hematology and Stem Cell Transplantation, University
Hospital Essen, University of Duisburg Essen, Essen, Germany; J rn C. Albring, Department
of Medicine A Hematology, Oncology, and Pneumology, University Hospital
M nster, University of M nster, M nster, Germany; Robert Seifert, Department of
Nuclear Medicine, University Hospital Essen, University of Duisburg Essen,
Essen, Germany, Department of Nuclear Medicine, University Hospital M nster,
University of M nster, M nster, Germany, and Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern,
Bern, Switzerland; Andrea Paccagnella, Nuclear Medicine Service, M. Bufalini
Hospital, Azienda Unit Sanitaria Locale Romagna,
Cesena, Italy; and Vladan Vučinić, Department of Hematology, Cellular
Therapy, Hemostaseology, and Infectious Diseases,
University Hospital Leipzig, University of Leipzig, Leipzig, Germany, and Department
of Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and
Immunology, Leipzig, Germany.
Visit the JNM
website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn.
###
Please visit the SNMMI Media Center for more information about molecular
imaging and precision
imaging. To schedule an interview with the researchers, please
contact Rebecca Maxey at (703) 652-6772 or [email protected].
About JNM and the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world s
leading nuclear medicine, molecular imaging and theranostics
journal, accessed 15 million times each year by practitioners around the
globe, providing them with the information they need to advance this rapidly
expanding field. Current and past issues of The Journal of Nuclear
Medicine can be found online at http://jnm.snmjournals.org.
JNM is published by the Society of Nuclear Medicine and
Molecular Imaging (SNMMI), an international scientific and medical organization
dedicated to advancing nuclear medicine, molecular imaging, and theranostics precision medicine that allows diagnosis and
treatment to be tailored to individual patients in order to
achieve the best possible outcomes. For more information, visit snmmi.org.